Literature DB >> 19118214

Integrins in immunity.

Rachel Evans1, Irene Patzak, Lena Svensson, Katia De Filippo, Kristian Jones, Alison McDowall, Nancy Hogg.   

Abstract

A successful immune response depends on the capacity of immune cells to travel from one location in the body to another--these cells are rapid migrators, travelling at speeds of microm/minute. Their ability to penetrate into tissues and to make contacts with other cells depends chiefly on the beta2 integrin known as LFA-1. For this reason, we describe the control of its activity in some detail. For the non-immunologist, the fine details of an immune response often seem difficult to fathom. However, the behaviour of immune cells, known as leukocytes (Box 1), is subject to the same biological rules as many other cell types, and this holds true particularly for the functioning of the integrins on these cells. In this Commentary, we highlight, from a cell-biology point of view, the integrin-mediated immune-cell migration and cell-cell interactions that occur during the course of an immune response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19118214     DOI: 10.1242/jcs.019117

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  128 in total

1.  β2 integrin induces TCRζ-Syk-phospholipase C-γ phosphorylation and paxillin-dependent granule polarization in human NK cells.

Authors:  Michael E March; Eric O Long
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

2.  GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice.

Authors:  Tibor Kempf; Alexander Zarbock; Christian Widera; Stefan Butz; Anika Stadtmann; Jan Rossaint; Matteo Bolomini-Vittori; Mortimer Korf-Klingebiel; L Christian Napp; Birte Hansen; Anna Kanwischer; Udo Bavendiek; Gernot Beutel; Martin Hapke; Martin G Sauer; Carlo Laudanna; Nancy Hogg; Dietmar Vestweber; Kai C Wollert
Journal:  Nat Med       Date:  2011-04-24       Impact factor: 53.440

3.  Structure of collagen receptor integrin α(1)I domain carrying the activating mutation E317A.

Authors:  Matti Lahti; Eva Bligt; Henri Niskanen; Vimal Parkash; Anna-Maria Brandt; Johanna Jokinen; Pekka Patrikainen; Jarmo Käpylä; Jyrki Heino; Tiina A Salminen
Journal:  J Biol Chem       Date:  2011-10-26       Impact factor: 5.157

4.  Early integrin binding to Arg-Gly-Asp peptide activates actin polymerization and contractile movement that stimulates outward translocation.

Authors:  Cheng-han Yu; Jaslyn Bee Khuan Law; Mona Suryana; Hong Yee Low; Michael P Sheetz
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-02       Impact factor: 11.205

5.  Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8(+) memory T cells.

Authors:  W H Kitchens; D Haridas; M E Wagener; M Song; A D Kirk; C P Larsen; M L Ford
Journal:  Am J Transplant       Date:  2011-09-22       Impact factor: 8.086

6.  The C-terminal αI domain linker as a critical structural element in the conformational activation of αI integrins.

Authors:  Gabriele Weitz-Schmidt; Thomas Schürpf; Timothy A Springer
Journal:  J Biol Chem       Date:  2011-09-30       Impact factor: 5.157

Review 7.  Integrins as therapeutic targets: lessons and opportunities.

Authors:  Dermot Cox; Marian Brennan; Niamh Moran
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

Review 8.  Reactive oxygen species in inflammation and tissue injury.

Authors:  Manish Mittal; Mohammad Rizwan Siddiqui; Khiem Tran; Sekhar P Reddy; Asrar B Malik
Journal:  Antioxid Redox Signal       Date:  2013-10-22       Impact factor: 8.401

9.  Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.

Authors:  Alan G Ramsay; Rachel Evans; Shahryar Kiaii; Lena Svensson; Nancy Hogg; John G Gribben
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

Review 10.  Integrins in Wound Healing.

Authors:  Leeni Koivisto; Jyrki Heino; Lari Häkkinen; Hannu Larjava
Journal:  Adv Wound Care (New Rochelle)       Date:  2014-12-01       Impact factor: 4.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.